Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.57 |
| ▸ | CA2 | P00918 | 8/20 | 0.57 |
| ▸ | CA4 | P22748 | 8/20 | 0.57 |
| ▸ | CA9 | Q16790 | 7/20 | 0.57 |
| ▸ | PLK1 | P53350 | 1/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.50 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | ELANE | P08246 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25979813 | 0.76 | MMP2 (0.41) | CA1CA2CA4CA9HTT | |
| SCHEMBL6755012 | 0.75 | ALDH1A1 (0.59) | CA1CA2CA4CA9HTT | |
| SCHEMBL3213248 | 0.75 | MMP2 (0.46) | CA1CA2CA4CA9HTT | |
| SCHEMBL6795755 | 0.72 | MAPT (0.43) | CA1CA2CA4CA9HTT | |
| SCHEMBL14243938 | 0.70 | MEN1 (0.52) | CA1CA2CA4CA9HTT | |
| SCHEMBL16986579 | 0.70 | AKR1B1 (0.39) | HTTALDH1A1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL7987717 | 0.69 | HTR6 (0.46) | HTTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL29148527 | 0.69 | MAPT (0.36) | CA1CA2HTTALDH1A1MEN1 | |
| SCHEMBL1986758 | 0.68 | PLK1 (1.00) | CA1CA2CA4CA9PLK1 | |
| SCHEMBL29779074 | 0.67 | MAPT (0.55) | CA1CA2CA9ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2948431-B1 | BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-03-13 | — | — | EP | disclosed |
| US-9446130-B2 | BTK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150353565-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2948431-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-12-02 | — | — | EP | disclosed |
| EP-2721009-B1 | PYRAZOLE DERIVATIVES USEFUL AS ALDOSTERONE SYNTHASE INHIBITORS | LILLY CO ELI (US) | 2015-08-12 | — | — | EP | disclosed |
| WO-2014116504-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014113942-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-07-31 | — | — | WO | disclosed |
| US-8778984-B2 | Aldosterone synthase inhibitor | ELI LILLY AND COMPANY (US) | 2014-07-15 | — | — | US | disclosed |
| US-8697744-B2 | Substituted 5,6-dihydro-4H-thiazolo[4,5-E]indazoles and their use as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA S.A. (CH) | 2014-04-15 | — | — | US | disclosed |
| US-20120322841-A1 | Aldosterone Synthase Inhibitor | ELI LILLY AND COMPANY (US) | 2012-12-20 | — | — | US | disclosed |
| US-20110319425-A1 | HETEROTRICYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2011-12-29 | — | — | US | disclosed |
| EP-2382219-A1 | HETEROTRICYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX Pharma S.A. (CH) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010079238-A1 | HETEROTRICYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353565-A1 | BTK INHIBITORS | BTK, SYK, LYN | CA1 4768/4885CA2 2145/4885CA4 4278/4885 |
| US-20110319425-A1 | HETEROTRICYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM1, GRM4, GRM2 | CA1 2356/4885CA2 686/4885CA4 2265/4885 |
| US-20120322841-A1 | Aldosterone Synthase Inhibitor | CYP21A2, CYP17A1, HSD11B1 | CA1 1250/4885CA2 723/4885CA4 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.